Study on the expression levels of antibodies against SARS-CoV-2 at different period of disease and its related factors in 192 cases of COVID-19 patients
Detection Principle
ImmunoAssay-Antibody
Target
IgM and IgG
Testing Method Category
Other Immuno assay
Testing Method
Shenzhen New Industries Biomedical Engineering Co.,Ltd [Snibe], China
Testing Method - Additional Info
Describing the kinetics prodfile of antibodies against SARS-CoV-2 and explore the related factor of antibodies expression against SARS-CoV-2 in covid-19 patients
Reported Performance
Positive test rate <7 days symptoms onset IgM: 14.7%, Positive test rate <7 days symptoms onset IgG: 26.4%; Positive test rate 8-14 days symptoms onset IgM: 56.6%; Positive test rate 8-14 days symptoms onset IgG: 66.5%; Positive test rate 15-21 days symptoms onset IgM: 82.8%; Positive test rate 15-21 days symptoms onset IgG: 91%; Positive test rate 22-28 days symptoms onset IgM: 84.9%; Positive test rate 22-28 days symptoms onset IgG: 94.8%; Positive test rate 29-35 days symptoms onset IgM: 75.5%; Positive test rate 29-35 days symptoms onset IgG: 93.5%; Positive test rate 36-42 days symptoms onset IgM: 67.4%; Positive test rate 36-42 days symptoms onset IgG: 94.9%; Positive test rate 43-49 days symptoms onset IgM: 62.5%; Positive test rate 43-49 days symptoms onset IgG: 92.3%; Positive test rate 50-56 days symptoms onset IgM: 58.7%; Positive test rate 50-56 days symptoms onset IgG: 96%; Positive test rate >56 days symptoms onset IgM: 41.2%; Positive test rate >56 days symptoms onset IgG: 92.2%
Sample Size
192 patients
Peer-reviewed
no
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements